Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
08:00am, Thursday, 24'th Oct 2024
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved wel
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
08:00am, Thursday, 24'th Oct 2024
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if a
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Wednesday, 23'rd Oct 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
03:09pm, Tuesday, 22'nd Oct 2024
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
09:35am, Tuesday, 22'nd Oct 2024
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of th
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
03:34pm, Friday, 11'th Oct 2024
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-tim
Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 10'th Oct 2024
The heavy selling pressure might have exhausted for Regeneron (REGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
09:45am, Thursday, 10'th Oct 2024
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF NYSE: SPY up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks a
Regeneron Gains 13.5% Year to date: How to Play the Stock?
03:20pm, Tuesday, 08'th Oct 2024
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
Should You Buy the Dip on This Top Growth Stock?
06:30am, Saturday, 05'th Oct 2024
The biotech needs to overcome an issue most drugmakers face at some point.
Stock Picks From Seeking Alpha's September 2024 New Analysts
08:00am, Friday, 04'th Oct 2024
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
04:01pm, Monday, 30'th Sep 2024
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
05:18pm, Friday, 27'th Sep 2024
Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administrat
